StockData
Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc. (ALZN) stock

ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026Score 4/30
$1.13−0.05 (-4.24%)

Close on Nov 17, 2026Market cap $5.45MP/E –Yield –

Alzamend Neuro ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

No ebitda figures for Alzamend Neuro

Alzamend Neuro has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Alzamend Neuro figures

See a number that looks wrong?